OBJECTIVES/HYPOTHESIS: Document survival, prognostic variables, and functional outcomes of patients with AJCC stage III or IV oropharyngeal cancer, treated with transoral laser microsurgery (TLM) +/- adjuvant therapy. STUDY DESIGN: Analysis of prospectively assembled data pertaining to the above-described patient cohort. METHODS: Patients treated with TLM for AJCC stage III or IV oropharyngeal cancer at Washington University School of Medicine from 1996 to 2006 were followed for a minimum of 2 years. Recurrence, survival, functional, and human papilloma virus data were analyzed. RESULTS: Eighty-four patients met inclusion criteria. Mean follow-up was 52.6 months. Overall AJCC stages were: III 15% and IV 85%. T stages were T1-2, 74%; T3-4, 26%. Eighty-three patients underwent neck dissection, 50 received adjuvant radiotherapy, and 28 received adjuvant chemoradiotherapy. Overall survival at 2 and 5 years was 94% and 88%, respectively. Disease-specific survival at 2 and 5 years was 96% and 92%, respectively. Six patients recurred (7%): locally (one), regionally (four), and distant (five). T stage, positive margins, and p16 status significantly impacted survival. The addition of adjuvant chemotherapy in high-risk patients did not significantly impact survival. Five patients (6%) had major surgical complications, but without mortality. Eighty-one percent of patients had acceptable swallowing function at last follow-up. Immediately postoperatively, 17% required G-tubes, which dropped to 3.4% of living patients at 3 years. CONCLUSIONS: In this population, our findings validate TLM +/- adjuvant therapy as a highly effective strategy for survival, locoregional control, and swallowing recovery in AJCC stage III and IV oropharyngeal cancer. Our finding also show that p16 positivity improves survival.
OBJECTIVES/HYPOTHESIS: Document survival, prognostic variables, and functional outcomes of patients with AJCC stage III or IV oropharyngeal cancer, treated with transoral laser microsurgery (TLM) +/- adjuvant therapy. STUDY DESIGN: Analysis of prospectively assembled data pertaining to the above-described patient cohort. METHODS:Patients treated with TLM for AJCC stage III or IV oropharyngeal cancer at Washington University School of Medicine from 1996 to 2006 were followed for a minimum of 2 years. Recurrence, survival, functional, and human papilloma virus data were analyzed. RESULTS: Eighty-four patients met inclusion criteria. Mean follow-up was 52.6 months. Overall AJCC stages were: III 15% and IV 85%. T stages were T1-2, 74%; T3-4, 26%. Eighty-three patients underwent neck dissection, 50 received adjuvant radiotherapy, and 28 received adjuvant chemoradiotherapy. Overall survival at 2 and 5 years was 94% and 88%, respectively. Disease-specific survival at 2 and 5 years was 96% and 92%, respectively. Six patients recurred (7%): locally (one), regionally (four), and distant (five). T stage, positive margins, and p16 status significantly impacted survival. The addition of adjuvant chemotherapy in high-risk patients did not significantly impact survival. Five patients (6%) had major surgical complications, but without mortality. Eighty-one percent of patients had acceptable swallowing function at last follow-up. Immediately postoperatively, 17% required G-tubes, which dropped to 3.4% of living patients at 3 years. CONCLUSIONS: In this population, our findings validate TLM +/- adjuvant therapy as a highly effective strategy for survival, locoregional control, and swallowing recovery in AJCC stage III and IV oropharyngeal cancer. Our finding also show that p16 positivity improves survival.
Authors: G Calais; M Alfonsi; E Bardet; C Sire; T Germain; P Bergerot; B Rhein; J Tortochaux; P Oudinot; P Bertrand Journal: J Natl Cancer Inst Date: 1999-12-15 Impact factor: 13.506
Authors: Arlene A Forastiere; Helmuth Goepfert; Moshe Maor; Thomas F Pajak; Randal Weber; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Clifford Chao; Glen Peters; Ding-Jen Lee; Andrea Leaf; John Ensley; Jay Cooper Journal: N Engl J Med Date: 2003-11-27 Impact factor: 91.245
Authors: Mitchell Machtay; David I Rosenthal; Diane Hershock; Heather Jones; Shirnett Williamson; Michael J Greenberg; Gregory S Weinstein; Victor M Aviles; Ara A Chalian; Randal S Weber Journal: J Clin Oncol Date: 2002-10-01 Impact factor: 44.544
Authors: David J Adelstein; Yi Li; George L Adams; Henry Wagner; Julie A Kish; John F Ensley; David E Schuller; Arlene A Forastiere Journal: J Clin Oncol Date: 2003-01-01 Impact factor: 44.544
Authors: Floyd Christopher Holsinger; Alexander D Sweeney; Kitti Jantharapattana; Ahmed Salem; Randal S Weber; Woong Youn Chung; Carol M Lewis; David G Grant Journal: Curr Oncol Rep Date: 2010-05 Impact factor: 5.075
Authors: James S Lewis; Wade L Thorstad; Rebecca D Chernock; Bruce H Haughey; James H Yip; Qin Zhang; Samir K El-Mofty Journal: Am J Surg Pathol Date: 2010-08 Impact factor: 6.394
Authors: Dana M Hartl; Alfio Ferlito; Carl E Silver; Robert P Takes; Sandro J Stoeckli; Carlos Suárez; Juan P Rodrigo; Andreas M Sesterhenn; Carl H Snyderman; David J Terris; Eric M Genden; Alessandra Rinaldo Journal: Eur Arch Otorhinolaryngol Date: 2011-05-12 Impact factor: 2.503
Authors: Shamir P Chandarana; Julia S Lee; Eric J P Chanowski; Assuntina G Sacco; Carol R Bradford; Gregory T Wolf; Mark E Prince; Jeffrey S Moyer; Avraham Eisbruch; Francis P Worden; Thomas J Giordano; Bhavna Kumar; Katrina G Cordell; Thomas E Carey; Douglas B Chepeha Journal: Head Neck Date: 2012-08-21 Impact factor: 3.147
Authors: Samir H Patel; Michael L Hinni; Richard E Hayden; William W Wong; Amylou C Dueck; Matthew A Zarka; Kelly K Curtis; Michele Y Halyard Journal: Head Neck Date: 2013-03-26 Impact factor: 3.147